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Abstract
The recent discovery of an ATP-binding cassette transporter, ABCA1, as an important regulator of high density lipoprotein (HDL)
metabolism and reverse cholesterol transport has facilitated the identification of novel variants associated with HDL cholesterol deficiency
states. We identified a subject with HDL cholesterol deficiency (4 mg/dl) who developed and died of complications related to cerebral
amyloid angiopathy (CAA). The proband had a compound heterozygous mutation. One mutation was a G3295T substitution with
conversion of asparagine to tyrosine (D1099Y) in ABCA1. The single-base substitution at codon 1099 resulted in the abolition of an RsaI
cleavage site. The proband and affected individuals having another mutation were heterozygotes for T5966C with phenylalanine converted
to serine (F2009S). The presence of the T5966C mutation was detected by restriction digestion with Hinf I. These variants were not
identified in over 400 chromosomes of healthy subjects. In the kindred, family members heterozygous for the ABCA1 variant exhibited low
levels of HDL cholesterol. Direct sequencing of all coding regions and splice site junctions of other HDL candidate genes revealed no
additional mutations, indicating that combined defective ABCA1 alleles may result in familial HDL deficiency. D 2002 Elsevier Science
B.V. All rights reserved.
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1. Introduction
The ATP-binding cassette transporter, ABCA1, is a mem-
ber of the ABC superfamily of proteins involved in the
active transport of substrates across cellular membranes.
Like other ABCA subclass transporters, the ABCA1 protein
is characterized by four domains [1–3]; two nucleotide
binding domains (NBDs) with conserved Walker A and B
motifs are located at the cytosolic face of the membrane.
NBDs provide energy for solute transport by hydrolyzing
ATP. Another two transmembrane domains consist of six
membrane-spanning helices for each, determining the spe-
cificity for the transported molecules. ABCA1 regulates apo-
lipoprotein-mediated lipid removal pathway from cells [4],
the initial step of reverse cholesterol transport. Decreased
cellular cholesterol efflux by mutant ABCA1 leads to re-
duced apolipoprotein (apo)A-I stability and rapid catabo-
lism resulting in high density lipoprotein (HDL) deficiency
[4–7].
Several of the ABC transporters have attracted consid-
erable interest due to implication in the pathogenesis of
diseases such as cystic fibrosis [8], adrenoleukodystrophy
[9], and macular degeneration [10]. Disorder linked to
ABCA1 mutations, Tangier disease (TD) [5,11,12] and
familial hypoalphalipoproteinemia (FHA) [13,14], are asso-
ciated with HDL cholesterol levels of < 10 and 20–35 mg/
dl, respectively. Both FHA and TD are assigned to the same
chromosomal region (9q31).
Observational studies have previously demonstrated an
inverse relationship between HDL cholesterol and CAD
even when total cholesterol levels are desirable [15].
Because low HDL syndromes are genotypically heteroge-
neous, understanding their molecular basis could explain the
essential role of HDL in plasma cholesterol homeostasis and
vascular disease. In view of the importance of ABCA1 gene
mutants in the development of TD, where there is typically
virtual absence of HDL cholesterol, we investigated a
kindred with similarly low HDL cholesterol but without a
history of TD. Our data indicate that a heterozygote com-
pound for mutation in ABCA1 may cause HDL deficiency
without the phenotypic abnormalities associated with TD.
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2. Materials and methods
2.1. Study subjects
The proband, a resident of Overland Park, KS, USA, had
markedly reduced HDL cholesterol (4 mg/dl) and apoA-I
(8 mg/dl) (Fig. 1, arrow). There was no significant medical
history until he suffered a stroke at age 67 and died one year
later from complications resulting from cerebral amyloid
angiopathy (CAA), as confirmed on necropsy. In addition to
the proband, 10 family members of the kindred were
screened. There was no history of cardiovascular disease
(CVD), and no other CVD risk factors, except for low HDL
cholesterol. Moreover, there were no clinical descriptors
suggestive of TD. Lipid, lipoprotein and apolipoprotein
levels of the proband (shown in bold) and family members
of the kindred are shown in Table 1. All subjects gave their
informed consent prior to participation.
2.2. PCR amplification and single strand conformation
polymorphism (SSCP) analysis
All exons of ABCA1 were amplified by PCR from geno-
mic DNA using primers and reaction conditions described
previously [5,13,14,16] except for the oligonucleotide pri-
mers made by us (Table 2). The primers for PCR were made
to amplify all coding regions and splice site junctions.
Exons of ABCA1 were designated by the nomenclature of
Santamarina-Fojo et al. [17]. For mutation analysis of
ABCA1, PCR product was mixed with 6X loading dye
(95% formamide, 20 mM EDTA, 0.05% bromophenol blue,
0.05% xylene cyanol FF), denatured for 10 min at 96 jC,
and placed on ice. This denatured PCR product was electro-
Fig. 1. Pedigree of the kindred showing HDL segregation of D1099Y and F2009S mutations. Horizontal line symbols indicates heterozygote carrier status for
the D1099Y mutation. The heterozygous subjects for F2009S mutation are indicated by vertical line symbols. The proband (compound mutation) depicted by
horizontal–vertical mixed line symbol is indicated by an arrow. Numbers represent HDL cholesterol levels of the family members.
Table 1
Levels of plasma lipids, lipoproteins and apolipoproteins of the kindred
Subjects Sex Age
(year)
TC TG HDL-C LDL-C ApoA-I ApoB
I-1 M 69 184 130 4 154 8 168
I-2 F 64 279 107 58 200 169 162
II-1 M 39 213 84 51 145 127 103
II-2 F 39 141 74 38 88 111 79
II-3 F 37 159 156 17 111 65 130
II-4 M 35 157 94 30 109 100 106
II-5 M 33 169 80 35 117 108 100
II-6 F 31 178 194 37 102 107 96
II-7 F 23 136 84 27 92 94 92
III-1 F 9 218 106 43 154 112 122
III-2 F 5 212 83 59 136 133 83
TC= total cholesterol; TG= triglyceride; HDL-C= high density lipoprotein
cholesterol; LDL-C= low density lipoprotein cholesterol; Apo = apolipo-
protein.
Lipid, lipoprotein and apolipoprotein levels are expressed as mg/dl.
Proband is shown in bold letter.
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phoresed for SSCP on nondenaturing 8% or 10% polyacry-
lamide gels at 5–10 W for approximately 24 h at room
temperature.
2.3. Sequencing of PCR-amplified DNA
PCR products showing SSCP-shifts of ABCA1 were
isolated by using the Qiagen PCR purification kit and
sequenced manually. To identify variants of other primary
HDL candidate genes in the proband, all exon regions of
apoA-I, lecithin cholesterol acyl transferase (LCAT), lip-
oprotein lipase (LPL), phospholipid transfer protein (PLTP)
and scavenger receptor class B type I (SR-BI) genes were
amplified and sequenced. The PCR primers were also used
for sequencing.
2.4. Restriction enzyme analysis
Genotypic was performed by PCR amplification of exon
23 followed by restriction digestion with RsaI for the 3295T
mutation, and amplification of exon 45 followed by diges-
tion with HinfI for the T5966C mutation. The restriction
fragments of exon 23 and exon 45 were separated by 2%
agarose gel and 10% polyacrylamide gel electrophoresis,
respectively.
2.5. Determination of plasma lipid levels
Plasma samples were obtained in EDTA tubes from in-
dividuals who had been fasting for 12–16 h. Levels of
plasma total cholesterol and triglycerides were measured
by enzymatic colorimetry methods using commercial kits
(Boehringer-Mannheim, Indianapolis, IN) and a Hitachi 747
automatic chemistry analyzer. HDL cholesterol levels were
determined after precipitation of apoB lipoproteins with he-
parin sulfate (1.3 g/l) and manganese chloride (0.092 M).
ApoA-I and apoB levels were measured by using commer-
cially available immunodiffusion plates (apoA-I, Tago, Bur-
lingame, CA; apoB, Behring Diagnostics, La Jolla, CA).
LDL cholesterol levels were calculated by using the formula
of Friedewald et al. [18].
2.6. Statistical analysis
Student’s t-test was used to compare the mean differ-
ences in lipid, lipoprotein, and apolipoprotein levels in the
presence or absence of ABCA1 mutation. The designated
level of significance was P < 0.05.
3. Results and discussion
The first mutation was heterozygous for a G3295T sub-
stitution that changes asparagine to tyrosine (D1099Y). The
single-base substitution at codon 1099 causes the abolition
of a RsaI cleavage site. The RsaI digested patterns for exon
23 PCR products of human ABC1 gene are shown in Fig. 2.
The proband and affected individuals having another muta-
tion were heterozygotes for T5966C with phenylalanine
converted to serine (F2009S). The presence of the T5966C
mutation was detected by restriction digestion with HinfI
for exon 45 PCR products (Fig. 3). The proband had a
compound mutation for D1099Y and F2009S (Fig. 1,
arrow). These point mutations were not detected following
the screening of more than 400 chromosomes of healthy
Caucasians.
Mean lipid levels was compared between carriers (+) and
noncarriers ( ) of the ABCA1 variants. Significant differ-
ences between (+) and ( ) subjects of D1099Y mutation
were noted for HDL cholesterol [(+), 27.3F 14.6 vs. ( ),
47.0F 12.9 mg/dl; P < 0.001] and apoA-I [(+), 83.0F 40.8
vs. ( ), 125.4F 23.7 mg/dl; P < 0.001] levels. The F2009S
mutation was also associated with low HDL cholesterol [(+),
17.0F 18.4 vs. ( ), 40.6F 13.9 mg/dl; P < 0.05] and apoA-
I [(+), 54.0F 65.1 vs. ( ) 114.0F 28.4 mg/dl; P < 0.05]
levels. Affected family members with the ABCA1 mutant
exhibited low levels of HDL cholesterol, although extremely
low HDL cholesterol and apoA-I levels were only detected in
the proband having a compound heterozygous mutation.
The amino acids at the D1099Y and F2009S mutation
sites are conserved between human and mouse, indicating a
potentially important biological function. The D1099Y
Table 2































Exons of the ABCA1 gene are designated by the nomenclature of
Santamarina-Fojo et al. [17].
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mutation occurs in a highly conserved hydrophobic linker
region between the sixth and seventh helix of each trans-
membrane domain of the ABCA1 protein, suggesting that it
may be more likely to impair the specificity for the trans-
ported molecules. On the other hand, the region affected by
F2009S mutation is within the C-terminal NBD. Thus, a
mutation in this domain may impair the ATP hydrolysis
necessary for transporter activity.
To rule out variants in other primary HDL candidate
genes in the kindred, we sequenced all coding regions and
splice site junctions for apoA-I, LCAT, LPL, PLTP and SR-
BI genes. However, no additional mutations were identified,
indicating that double defective ABCA1 alleles may result in
familial HDL deficiency.
The proband died of CAA associated with very low HDL
level at age 68. Isolated low HDL cholesterol was observed
at least 5 years before the diagnosis of CAAwas established.
The very low HDL might be caused by a compound
mutation in ABCA1, thereby impairing the ATP hydrolysis
necessary for transporter activity and the specificity for the
transported molecules of ABCA1 protein. While five addi-
tional members of this kindred are heterozygous for the
D1099Y allele, they are relatively or considerably younger
and have not yet manifested CVD. One carrier member for
F2009Y heterozygous mutation also had no cardiovascular
symptom and is younger. It is conceivable that subjects with
the heterozygous mutation have subnormal or normal HDL
levels during youth because age-related decreases in HDL
cholesterol and increases in atherosclerosis have coincided
with ABCA1 variants [19]. A longitudinal study in this
family may provide further insight as to the extent of the
association between the ABCA1 variant identified herein and
CVD.
In conclusion, the novel ABCA1 mutation identified in
this study segregated with low HDL cholesterol in the
kindred, and was not detected in more than 400 chromo-
somes of healthy subjects. The proband, a compound heter-
ozygote for the two variants, neither manifested TD nor
CVD. Whether mutations in ABCA1 reported herein con-
tribute to the development or progression of atherosclerosis
will need to be explored in further studies. The present study
provides additional data demonstrating the complexity,
diversity and marked phenotypic heterogeneity of low
HDL syndromes.
Fig. 3. Restriction digestion analysis of carriers and noncarriers. The
presence of the T5966C mutation was detected by restriction digestion with
HinfI. Heterozygous carriers for the T5966C mutation are shown in lanes 1
and 4. And lanes 2 and 3 are digested patterns of noncarriers. The sizes of
HinfI-digested band in mutant and normal PCR products are depicted at the
bottom.
Fig. 2. The RsaI digested patterns for exon 23 PCR products of human
ABCA1 gene. In normal subjects, 229-bp fragment corresponding to the full-
length PCR amplification product is observed (lanes 1 and 4). Heterozygote
for mutation is cleaved to fragments of 229, 174, and 55 bp representing one
mutant allele and one normal allele (lanes 2 and 3). Lane 5 is 50-bp DNA
ladder marker (MBI Fermentas). The sizes of RsaI-digested band in mutant
and normal PCR products are depicted at the bottom.
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